IBS Rates Nearly Doubled During the Pandemic

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 1, 2025.

via HealthDay

MONDAY, July 1, 2025 — The COVID-19 pandemic took a toll on Americans’ guts, researchers report.

Gut disorders like irritable bowel syndrome (IBS) increased significantly during the COVID-19 pandemic, a new study says.

Rates of IBS nearly doubled among U.S. adults, rising from around 6% in May 2020 to about 11% in May 2022, results show.

Other gut health problems like constipation also increased, researchers report in the journal Neurogastroenterology & Motility.

“Rates of digestive issues such as irritable bowel syndrome and chronic idiopathic constipation rose significantly,” lead researcher Dr. Christopher Almario, a gastroenterologist at Cedars-Sinai Medical Center in Los Angeles, said in a news release.

“These findings underscore the significant toll the pandemic has taken on digestive health,” Almario added.

Conditions like IBS and chronic constipation are driven by complex interactions between the gut and the nervous system, researchers said in background notes.

“These disorders involve chronic gastrointestinal symptoms that are often triggered or worsened by psychological stress,” Almario said.

Researchers figured that more people might have developed a gut health disorder during the pandemic, from the effect of COVID infection on the digestive system as well as the stress from social distancing, isolation and fear of infection.

For the study, researchers analyzed data from more than 160,000 U.S. adults who participated in a national online survey from May 2020 to May 2022. Participants completed questionnaires covering digestive symptoms, mental health and lifestyle changes.

People with IBS most commonly reported suffering from mixed IBS, a type where the patient has both diarrhea and constipation, results show.

“This research calls for a renewed focus on gastrointestinal health in the post-pandemic era,” senior researcher Dr. Brennan Spiegel, director of health services research for Cedars-Sinai, said in a news release.

Sources

  • Cedars-Sinai, news release, June 27, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-07-02 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords